

L Number	Hits	Search Text	DB	Time stamp
1	2296	("514/183,252.1").CCLS	USPAT	2004/08/22 13:28
2	1066	("544/358,398").CCLS	USPAT	2004/08/22 13:29
3	0	("514/183,252.1").CCLS) and IK2	USPAT	2004/08/22 13:29
4	491	("514/183,252.1").CCLS) and diabetes	USPAT	2004/08/22 13:29
5	53	("544/358,398").CCLS) and diabetes	USPAT	2004/08/22 13:29
6	7	((("514/183,252.1").CCLS) and diabetes) and ((("544/358,398").CCLS) and diabetes)	USPAT	2004/08/22 13:29

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 May 12 EXTEND option available in structure searching  
NEWS 4 May 12 Polymer links for the POLYLINK command completed in REGISTRY  
NEWS 5 May 27 New UPM (Update Code Maximum) field for more efficient patent  
SDIs in CAplus  
NEWS 6 May 27 CAplus super roles and document types searchable in REGISTRY  
NEWS 7 Jun 28 Additional enzyme-catalyzed reactions added to CASREACT  
NEWS 8 Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,  
and WATER from CSA now available on STN(R)  
NEWS 9 Jul 12 BEILSTEIN enhanced with new display and select options,  
resulting in a closer connection to BABS  
NEWS 10 Jul 30 BEILSTEIN on STN workshop to be held August 24 in conjunction  
with the 228th ACS National Meeting  
NEWS 11 AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display  
fields  
NEWS 12 AUG 02 CAplus and CA patent records enhanced with European and Japan  
Patent Office Classifications  
NEWS 13 AUG 02 STN User Update to be held August 22 in conjunction with the  
228th ACS National Meeting  
NEWS 14 AUG 02 The Analysis Edition of STN Express with Discover!  
(Version 7.01 for Windows) now available  
NEWS 15 AUG 04 Pricing for the Save Answers for SciFinder Wizard within  
STN Express with Discover! will change September 1, 2004

NEWS EXPRESS JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:13:20 ON 22 AUG 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:13:30 ON 22 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 AUG 2004 HIGHEST RN 729615-76-3

DICTIONARY FILE UPDATES: 21 AUG 2004 HIGHEST RN 729615-76-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>


Uploading C:\Program Files\Stnexp\Queries\0990015.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

FULL SEARCH INITIATED 10:13:52 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1094 TO ITERATE

100.0% PROCESSED 1094 ITERATIONS

72 ANSWERS

SEARCH TIME: 00.00.01

L2 72 SEA SSS FUL L1

=&gt; file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.42

155.63

FILE 'CAPLUS' ENTERED AT 10:13:57 ON 22 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Aug 2004 VOL 141 ISS 9

FILE LAST UPDATED: 20 Aug 2004 (20040820/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=&gt; s l2

L3 40 L2

=&gt; d l3 fbib hitstr abs total

L3 ANSWER 1 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:726503 CAPLUS

DN 139:349795

TI Structural Identification of Nonvolatile Dimerization Products of Glucosamine by Gas Chromatography-Mass Spectrometry, Liquid Chromatography-Mass Spectrometry, and Nuclear Magnetic Resonance Analysis

AU Jun, Mira; Shao, Yu; Ho, Chi-Tang; Koetter, Uwe; Lech, Stanley

CS Department of Food Science, Rutgers University, New Brunswick, NJ, 08901-8520, USA

SO Journal of Agricultural and Food Chemistry (2003), 51(21), 6340-6346

CODEN: JAFCAU; ISSN: 0021-8561

PB American Chemical Society

DT Journal

LA English


IT 17460-13-8, Deoxyfructosazine

RL: FMU (Formation, unclassified); FORM (Formation, nonpreparative)  
(structural identification of nonvolatile dimerization products of glucosamine by GC-MS, LC-MS, and NMR)

RN 17460-13-8 CAPLUS

CN 1,2,3,4-Butanetetrol, 1-[5-[(2S,3R)-2,3,4-trihydroxybutyl]pyrazinyl]-,  
(1R,2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The degradation profile of glucosamine bulk form stressed at 100°C for 2 h in an aqueous solution was studied. Column chromatog. of acetylated product mixture led to isolation of two pure compds. and a mixture of at least 3 isomers. 5-(Hydroxymethyl)-2-furaldehyde (5-HMF) and 2-(tetrahydroxybutyl)-5-(3',4'-dihydroxy-1'-trans-butenyl)pyrazine, resp. were identified by utilizing a variety of anal. techniques, such as GC-MS, LC-MS, online UV spectrum, 1H and 13C NMR, and DEPT, as well as 1H-1H COSY. 2-(Tetrahydroxybutyl)-5-(2',3',4'-trihydroxybutyl)pyrazine was also identified, commonly known as deoxyfructosazine. In addition, glucosamine solid dosage form was exposed to 40°C/75% relative humidity for 10 wk. Methanol extract of glucosamine solid dosage form was analyzed after acetylation by LC-MS, resulting in degradants. Plus, deoxyfructosazine and 2,5-bis(tetrahydroxybutyl)pyrazine (fructosazine) were also determined. Furthermore, the mechanisms of formation of identified degradation products are proposed and briefly discussed.

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2003:193525 CAPLUS  
DN 139:224171  
TI Reduction mechanism of tetrazolium salt XTT by a glucosamine derivative  
AU Shimamura, Tomoko; Takamori, Atsuko; Ukeda, Hiroyuki; Sawamura, Masayoshi  
CS Department of Bioresources Science, Faculty of Agriculture, Kochi University, Kochi, 783-8502, Japan  
SO Bioscience, Biotechnology, and Biochemistry (2003), 67(2), 295-299  
CODEN: BBBIEJ; ISSN: 0916-8451  
PB Japan Society for Bioscience, Biotechnology, and Agrochemistry  
DT Journal  
LA English  
IT 17460-13-8, Deoxyfructosazine  
RL: PKT (Pharmacokinetics); BIOL (Biological study)  
(reduction mechanism of tetrazolium salt XTT by a glucosamine derivative)  
RN 17460-13-8 CAPLUS  
CN 1,2,3,4-Butanetetrol, 1-[5-[(2S,3R)-2,3,4-trihydroxybutyl]pyrazinyl]-, (1R,2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

g. III (dried at 80°/10-3 mm. over P2O5 and recrystd. from 1:10 H2O-iso-PrOH), m. 161-2°,  $[\alpha]_{23D} -78^\circ$  (c 0.6, H2O), Rf 0.42 (8:7:6 IV-iso-AmOH-H2O). To 1.24 g. III in 50 cc. 6% H2O2 was added 2 g. NaOH, the mixture warmed gradually to 80°, treated with 3 cc. perhydrol, heated until the Fehling test was neg. and acidified with 2N HNO3 to give 0.19 g. crystalline precipitate, which in 10 cc. 2N NH4OH after evaporation and treatment with aqueous EtOH and Carboraffin, gave the crystalline NH4 salt, which in 5 cc. 2N NH4OH was acidified with 2N HNO3 to yield 2,5-pyrazine-dicarboxylic acid (V), m. 188-89°; di-Me ester, oil, b. 120-40°/10-3 mm. III (6 g.) in 100 cc. 2N HCl, on hydrogenation at 19.5°/756 mm. with 0.5 g. prehydrogenated PdO, filtration, evaporation with EtOH, dissoln. in 6 cc. H2O and 35 cc. EtOH gave 2.5 g. chromatographically pure 1-amino-1-deoxy-D-fructose-HCl (Va), m. 114-16°, which retained 1/4 mole H2O (even after drying at 20°/12 mm. over P2O5). The mother liquor from Va was evaporated to a sirup which was suspended in 100 cc. 5:5:1:3 AcOEt-IV-ACOH-H2O; 50 cc. was chromatographed on a cellulose powder column using the Fischer-Nebel method. After a forerun of 800 cc. 15 cc. fractions were collected. Fractions 66-100 reduced 1,2-(O2N)2C6H4, and these were rechromatographed. The combined fractions 66-78 yielded a single substance (VI), Rva 1.26  $\pm$  0.05. Fractions 88-100 gave pure Va, and fractions 79-87 gave mixts. of Va and VI. VI in H2O evaporated repeatedly with H2O gave a brown sirup which in 10 cc. H2O with 4-O2NC6H4NHNH2 (VII), AcONa, and AcOH heated 2 hrs. at 90° and, after 14 hrs. at 0°, washing with H2O, and EtOH-Et2O, and boiling several hrs. with H2O, gave from the filtrate 0.25 g. N-acetyl-N'-(p-nitrophenyl)hydrazine, m. 212-13°. The hot-H2O-insol. residue, in 100 cc. EtOH, evaporated to 30 cc. yielded 0.145 g. 3-deoxy-D-erythro-hexose p-nitrophenylosazone, violet, m. 248° (absolute EtOH), identical with the compound prepared from Me 3-deoxy- $\alpha$ -D-arabino-hexoside on heating with dilute H2SO4 at 90°, neutralizing with N NaOH, and treating as above with VII. Va with PhNHNH2 gave 55% D-arabino-hexose phenylosazone. 1-Acetamido-1-deoxy-D-fructose (3 g.) in 4.5 g. Et2NH and 30 cc. MeOH was heated 2 hrs. at 90° under O, cooled, washed with MeOH and cold H2O to give I, N: C(CHROH):CH.N:C(CHROH).CH [R = CH(OH)CH(OH)CH2OH], m. 237° (decomposition) (H2O), Rf (8:7:6 IV-iso-AmOH-H2O) 0.37. I reduced in 2N HCl at room temperature gave 49% Va. Inasmuch as the hydrogenation and hydrolysis of III gave 1 mole each of 1-amino-1-deoxy-D-fructose and 1-amino-1,3-dideoxy-D-erythro-hexulose, the structure of III is putatively CH:N.C(CH2R):CH.N:CCHROH, [R = CH(OH)CH(OH)CH2OH].

=> s l3 and hypoglycaemic

L4 0 L3 AND HYPOGLYCAEMIC

=> s l3 and diabetes

L5 4 L3 AND DIABETES

=> s l3 and diabetes I

L6 0 L3 AND DIABETES I

=> s l3 and diabetes II

L7 0 L3 AND DIABETES II

=> s l3 and insuline


L8 0 L3 AND INSULINE

=> d l5 fbib hitstr abs total

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2001:489238 CAPLUS  
 DN 135:82010  
 TI Association of deoxyfructosazine and a peroxisome proliferating  
 $\gamma$ -activated receptor agonist antidiabetic  
 IN Evers, Michel  
 PA Aventis Pharma S.A., Fr.  
 SO PCT Int. Appl., 10 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA French  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047529	A2	20010705	WO 2000-FR3606	20001220
	WO 2001047529	A3	20021024		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				FR 1999-16359	A 19991223
	FR 2802815	A1	20010629	FR 1999-16359	19991223
IT	17460-13-8, Deoxyfructosazine				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (association of deoxyfructosazine and peroxisome proliferating $\gamma$ -activated receptor agonist antidiabetic)				
RN	17460-13-8 CAPLUS				
CN	1,2,3,4-Butanetetrol, 1-[5-[(2S,3R)-2,3,4-trihydroxybutyl]pyrazinyl]-, (1R,2S,3R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




AB The invention concerns the association of deoxyfructosazine and a peroxisome proliferating  $\gamma$ -activated receptor (PPAR- $\gamma$ ) agonist antidiabetic, pharmaceutical compns. containing the association and their use for preventing and/or treating type 2 **diabetes** and its complications. The dosages for deoxyfructosazine and the PPAR- $\gamma$  agonist (e.g., troglitazone) can be 50-600 and 200-600 mg/day, resp.

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2001:489236 CAPLUS

DN 135:82009  
 TI Association of deoxyfructosazine and a sulfonylurea antidiabetic  
 IN Evers, Michel  
 PA Aventis Pharma S.A., Fr.  
 SO PCT Int. Appl., 14 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA French  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047527	A1	20010705	WO 2000-FR3603	20001220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2802814	A1	20010629	FR 1999-16358	A 19991223
	FR 2802814	B1	20020222	FR 1999-16358	19991223
IT	17460-13-8, Deoxyfructosazine				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(association of deoxyfructosazine and sulfonylurea antidiabetic)				
RN	17460-13-8 CAPLUS				
CN	1,2,3,4-Butanetetrol, 1-[5-[(2S,3R)-2,3,4-trihydroxybutyl]pyrazinyl]-, (1R,2S,3R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



AB The invention concerns the association of deoxyfructosazine and an sulfonylurea antidiabetic, pharmaceutical compns. containing the association and their use for preventing and/or treating type-2 **diabetes** and its complications. The dosages of deoxyfructosazine an sulfonylurea antidiabetic (e.g., glimepiride) can be 50-600, and 0.5-6 mg/day, resp.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2001:489231 CAPLUS  
 DN 135:82006  
 TI Combinations of deoxyfructosazine and an antidiabetic of the biguanide family  
 IN Evers, Michel



PA Aventis Pharma S.A., Fr.  
 SO PCT Int. Appl., 9 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA French  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047522	A2	20010705	WO 2000-FR3604	20001220
	WO 2001047522	A3	20020404		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				FR 1999-16357	A 19991223
	FR 2802813	A1	20010629	FR 1999-16357	19991223
IT	17460-13-8, Deoxyfructosazine				
	RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)				
	(combinations of deoxyfructosazine and an antidiabetic of the biguanide family)				
RN	17460-13-8 CAPLUS				
CN	1,2,3,4-Butanetetrol, 1-[5-[(2S,3R)-2,3,4-trihydroxybutyl]pyrazinyl]-, (1R,2S,3R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




AB The invention concerns the association of deoxyfructosazine and an antidiabetic of the biguanide family, and pharmaceutical compns. and their use for preventing and/or treating type 2 **diabetes** and its complications.

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2001:489195 CAPLUS  
 DN 135:81999  
 TI Combination of deoxyfructosazine and an antidiabetic inhibiting alpha-glucosidase  
 IN Evers, Michel  
 PA Aventis Pharma S.A., Fr.  
 SO PCT Int. Appl., 9 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047468	A2	20010705	WO 2000-FR3605	20001220
	WO 2001047468	A3	20021128		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2802816	A1	20010629	FR 1999-16360	A 19991223
IT	17460-13-8, Deoxyfructosazine			FR 1999-16360	19991223
	RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (combination of deoxyfructosazine and an antidiabetic inhibiting alpha-glucosidase)				
RN	17460-13-8 CAPLUS				
CN	1,2,3,4-Butanetetrol, 1-[5-[(2S,3R)-2,3,4-trihydroxybutyl]pyrazinyl]-, (1R,2S,3R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



AB The invention concerns the combination of deoxyfructosazine and an antidiabetic inhibitor of glucosidase, pharmaceutical compns. containing said combination, and their use for preventing and/or treating type 2 **diabetes** and its complications.

=&gt; log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

223.94

379.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-30.80

-30.80

STN INTERNATIONAL LOGOFF AT 10:16:16 ON 22 AUG 2004